Skip to Main Content

Paper Details

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.
NPJ Breast Cancer
6
2023
Author NameAffiliation
Chiara CortiEuropean Institute of Oncology IRCCS
Alberto ZambelliIRCCS Humanitas Research Hospital
Alberto ZambelliHumanitas University
Carmen CriscitielloEuropean Institute of Oncology IRCCS
Carmen CriscitielloUniversity of Milan
Giuseppe CuriglianoEuropean Institute of Oncology IRCCS
Giuseppe CuriglianoUniversity of Milan
  • 1 - 7

Datasets

Release 1.2